• About
    • Company Overview
    • Management Team
    • Board of Directors
    • Science Advisors
    • Neurology Advisors
    • Ophthalmology Advisors
    • Contacts
  • Science
    • Publications
    • Collaborators
  • Pipeline
    • Infantile Neuroaxonal Dystrophy (INAD)
    • Friedreich’s Ataxia (FA)
    • Amyotrophic Lateral Sclerosis (ALS)
    • Progressive Supranuclear Palsy (PSP)
    • Dry AMD
    • Future Targets
  • Patient Resources
    • Expanded Access Policy
    • Clinical Trials
    • Additional Resources
  • News & Events
    • Press Releases
    • News
    • Events
    • Videos
  • Careers
HomeSciencePublicationsIsotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson’s disease

Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson’s disease

Parkinson’s disease (PD) is the second most common neurodegenerative disease, affecting 1–2% of the population over 65 years of age. A role for oxidative stress in PD etiology is supported by a vast literature, including evidence of polyunsaturated fatty acid (PUFA) peroxidation products, including 4-hydroxynonenal (HNE) and malondialdehyde (MDA), the major products of PUFA oxidation in post-mortem tissue for patients with PD. Furthermore, oxidized PUFA initiate further cellular injury through oxidation of DNA, proteins and other cellular targets, including those linked to PD: dopamine (DA) and importantly alpha-synuclein. PUFA are essential components that make up a substantial fraction of lipid membranes. PUFA, specifically linoleic (LA; 18:2n − 6) and -linolenic (ALA; 18:3n − 3) acids, are early targets of oxidation by reactive oxygen species (ROS) (Fig. 1). This damage deteriorates the properties of lipid membranes such as fluidity (Dobretsov et al., 1977). Moreover, oxidized PUFA can damage other biomolecules, most notably proteins and DNA, through reactive carbonyl products (RCP) suchasHNE, 4-hydroxyhexenal(HHE),malondialdehyde (MDA) and acrolein (Lim et al., 2004).

Read more…

About
Science
  • Publications
Pipeline
  • Clinical
  • Preclinical
  • Future Targets
Patient Resources
  • Expanded Access Policy
News & Events
Careers
RETROTOPE, 4300 EL CAMINO REAL, SUITE 201, LOS ALTOS, CA 94022
Copyright ©️ 2015-2021 Retrotope Inc.
You are leaving Retrotope’s website. Retrotope does not guarantee the accuracy or completeness of the information contained on any third-party sites, nor does it endorse any of the opinions or information contained on those sites. Please click CONFIRM to continue. CONFIRM